English Release 28-March 2015
- President's Secretariat
- President of India congratulates Saina Nehwal for achieving World No.1 ranking in Badminton
- President of India congratulates ISRO for the successful launch of PSLV-C27
- Press Communique
- President of India condoles the passing away of P R Kyndiah
- President of India condoles the passing away of Brig. T. Sailo
- Tribal Youth attending the Seventh Tribal Youth Exchange Programme call on the President
- Prime Minister's Office
- PM congratulates scientists on the launch of IRNSS-1D satellite
- PM congratulates Saina Nehwal on becoming World No. 1
- Sri Mata Amritanandamayi Devi calls on PM
- All party delegation of MPs from Tamil Nadu calls on PM
- PM tweets about his upcoming 3-nation tour
- PM greets the people on the occasion of Ram Navami
- Department of Space
- PSLV-C27 Successfully Launches
India's Fourth Navigation Satellite IRNSS-1D
- Min of Personnel, Public Grievances & Pensions
- Blood Sugar test mandatory for every pregnant woman: Dr. Jitendra Singh
- Min of Textiles
- India Carpet Expo 2015 attains new heights
Ministry of Health and Family Welfare11-March, 2011 15:34 IST
|The Central Government has prohibited six drugs on the recommendations of the Expert Committee constituted by DTAB in view of the safety issues involved in the use of these drugs by a Gazette Notification dated 10.02.2011 with immediate effect. The names of these drugs along with the brief reasons for their ban are furnished below:|
1. Nimesulide formulations in children below 12 years of age - Nimesulide containing products are not permitted in many countries in children under 12 years of age. The drug has been considered to be hepatotoxic and children are considered more susceptible to hepatotoxicity.
2. Cisapride and its formulations for human use - Use of this drug is reported to be associated with increased risk of serious cardiac arrhythmia.
3. Phenylpropanolamine and its formulations for human use - Use of this drug is associated with risk of hypertensive episodes like cardiac congestive failures and hemorrhagic strokes.
4. Human Placental Extract and its formulations for human use - There is no clear evidence of efficacy of this drug in most of the conditions and there are safety concerns like transmission of blood borne infections, immunoreactions and unwanted exposure to hormones associated with its use.
5. Sibutramine and its formulations for human use - Use of this drug is associated with increased risk of cardiovascular events such as heart attack and stroke.
6. R-Sibutramine and its formulations for human use - Use of this drug is associated with increased risk of cardiovascular events such as heart attack and stroke.
Apart from the aforementioned six drugs banned recently, the following drugs have been banned during the last three years:
1. Rosiglitazone, on 12th November, 2010 - Use of this drug is associated with increased risk of cardiovascular events such as congestive heart failure and myocardial infarction.
2. Rimonabant, on 11th December, 2009 - Use of this drug is associated with increased risk of psychiatric side effects.
3. Diclofenac and its formulations for animal use, on 4th July, 2008 - Extensive use of this drug in animals was leading to harmful effects on vultures. The vulture population was depleting as it was observed that vultures fed on carcass of animals treated with diclofenac were dying.
The decision to ban or withdraw a drug by the regulatory authorities is normally based on the risk assessment process, which is influenced by a number of factors such as disease pattern in a country, indications and dosages of the drug permitted, varying reactions of certain ethnic groups in a given population, availability of safer substitutes and overall safety profile of the drug. These conditions are different for different countries. It is for this reason that a drug banned / restricted in one country may continue to be marketed in other countries. There is a well laid out mechanism in India to review the status of the drug formulations as and when any serious adverse event is reported in the International journals, WHO Newsletters or when a drug formulation is reported to have been banned / withdrawn in some countries. The use of the drug, so reported, is assessed in consultation with the expert committees set up for the purpose, based on available technical information, benefit-risk ratio, local needs and availability of safer alternatives etc. The Central Government prohibit manufacture and sale of drugs in the country under Section 26A of the Drugs and Cosmetics Act, 1940.
This information was given by Minister of Health & Family Welfare Sh. Ghulam Nabi Azad in reply to a question in the Lok Sabha today.
(Release ID :70841)